Diabetes is a chronic progressive metabolic disease caused by insulin deficiency or insulin
resistance. In spite of the availability of several antihyperglycaemics, there is a need for the …

Introduction: The sodium-glucose co-transporter 2 (SGLT2) is ascribed to target renal tubular
glucose re-absorption, and its inhibition has been proved to induce glucosuria which …

Diabetes mellitus is the global health issue and become an alarming threat in the modern
era where human lifestyle gets compromised with modernization. According to the latest …

Diabetes mellitus (DM) is one of the leading causes of death by World Health Organization
in 2019 and is considered a significant cause of other diseases including heart attack …

Diabetes is one of the most common disorders that substantially contributes to an increase
in global health burden. As a metabolic disorder, diabetes is associated with various …

SGLT2 inhibitors were promising and novel antidiabetic drugs which suppressed glucose
reabsorption and increased urinary glucose exertion. This review paper are aimed to …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors facilitate urine glucose excretion by
reducing glucose reabsorption, leading to ameliorate glycemic control. While the main …

Plasma glucose is continuously filtered through the glomerulus and then is reabsorbed via
the transcellular transport system of proximal tubules in the kidney. The glucose …

Inhibiting sodium–glucose co-transporters (SGLT1/SGLT2), which have a key role in the
absorption of glucose in the kidney and/or GI tract has been proposed as a novel therapeutic …

Diabetes mellitus is a disease that affects millions of people worldwide and its prevalence is
estimated to rise in the future. Billions of dollars are spent each year around the world in …